When to Use Monofer versus Venofer in Hospital
Monofer (ferric derisomaltose) should be preferred over Venofer (iron sucrose) in hospitalized patients when rapid, complete iron repletion is needed in a single visit, as Monofer allows up to 1000-2000 mg administration in 20-30 minutes versus Venofer's maximum of 200-500 mg requiring multiple visits. 1, 2, 3
Key Decision Algorithm
Choose Monofer when:
- Single-dose complete repletion is desired: Monofer can deliver 1000 mg (or up to 20 mg/kg, max 1500-2000 mg) in one 20-30 minute infusion 1, 2
- Minimizing hospital visits/infusions: Particularly important for inpatient efficiency and patient convenience
- Patients weighing ≥50 kg: Standard 1000 mg single dose 2
- Patients weighing <50 kg: Dose as 20 mg/kg actual body weight 2
- Cardiovascular benefit matters: Monofer is the first IV iron showing statistically significant reduction in cardiovascular death in heart failure patients 1
Choose Venofer when:
- Hemodialysis patients requiring maintenance dosing: Venofer 100 mg per dialysis session is FDA-approved and well-established 3
- Pediatric patients ≥2 years: Venofer has specific pediatric dosing (0.5 mg/kg, max 100 mg) 3
- Lower single doses preferred: Maximum 200-500 mg per infusion depending on indication 3
- Cost constraints exist: Venofer is typically less expensive, though requires multiple visits 4
Administration Differences
Monofer Dosing:
- Adults ≥50 kg: 1000 mg IV over ≥20 minutes 2
- Adults <50 kg: 20 mg/kg IV over ≥20 minutes 2
- Dilute in 100-500 mL normal saline (concentration >1 mg/mL) 2
- Single total dose infusion capability 1
Venofer Dosing:
- HDD-CKD: 100 mg per dialysis session over 2-5 minutes or 15 minutes (total course 1000 mg) 3
- NDD-CKD: 200 mg × 5 doses over 14 days 3
- PDD-CKD: 300 mg × 2, then 400 mg over 28 days 3
- Requires multiple visits to achieve total iron repletion 1
Safety Considerations
Both formulations have comparable safety profiles 1, 5, 6:
- Hypersensitivity reactions: Similar rates (Monofer 0.3%, Venofer comparable) 1, 5
- Anaphylaxis: Extremely rare with both (<0.1%) 1
- Hypophosphatemia: Less common with Monofer compared to ferric carboxymaltose; not a significant concern with Venofer 1, 7
- Cardiovascular events: Monofer showed significantly lower composite cardiovascular adverse events versus Venofer in CKD patients (4.1% vs 6.9%, P=0.025) 5
Critical Safety Requirements for Both:
- Monitor patients for ≥30 minutes post-infusion 2, 3
- Have resuscitation equipment immediately available 2, 3
- Monitor for extravasation (can cause long-lasting brown discoloration) 2
Efficacy Comparison
Meta-analyses show no significant difference in hemoglobin response between Monofer and Venofer 6, 8:
- Hemoglobin change at week 4: No difference (MD 0.09 g/dL) 6
- Hemoglobin change at week 8: No difference (MD 0.04 g/dL) 6
- However, Monofer produces faster ferritin rise at week 2 (P=0.02) 5, 8
Clinical Populations
Both are effective in:
Venofer has specific advantage in:
Practical Hospital Considerations
Monofer is superior for inpatient efficiency:
- Single infusion completes therapy (versus 5-10 visits with Venofer) 1
- Shorter total infusion time for complete repletion
- Reduces nursing time and IV access complications
- Better for patients with difficult IV access
Common Pitfall: Do not check iron parameters within 4 weeks of total dose infusion—circulating iron interferes with assays 1
Monitoring: Check CBC and iron parameters (ferritin, TSAT) at 4-8 weeks post-infusion for both formulations 1